Nigeria

Nigeria

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
9.9 (8.61 - 11.33) 2019 Modelled IHME
10.18 (8.88 - 11.68) 2018 Modelled IHME
10.38 (9.04 - 11.89) 2017 Modelled IHME
10.49 (9.13 - 12.06) 2016 Modelled IHME
10.6 (9.19 - 12.17) 2015 Modelled IHME
10.81 (9.36 - 12.42) 2014 Modelled IHME
11.1 (9.63 - 12.77) 2013 Modelled IHME
11.44 (9.94 - 13.17) 2012 Modelled IHME
11.79 (10.25 - 13.56) 2011 Modelled IHME
12.09 (10.52 - 13.90) 2010 Modelled IHME
12.35 (10.74 - 14.18) 2009 Modelled IHME
12.58 (10.95 - 14.43) 2008 Modelled IHME
12.81 (11.16 - 14.68) 2007 Modelled IHME
13.05 (11.36 - 14.95) 2006 Modelled IHME
13.31 (11.59 - 15.24) 2005 Modelled IHME
13.65 (11.92 - 15.63) 2004 Modelled IHME
14.06 (12.30 - 16.10) 2003 Modelled IHME
14.46 (12.66 - 16.56) 2002 Modelled IHME
14.77 (12.95 - 16.90) 2001 Modelled IHME
14.92 (13.08 - 17.06) 2000 Modelled IHME
14.95 (13.10 - 17.11) 1999 Modelled IHME
14.97 (13.11 - 17.15) 1998 Modelled IHME
14.99 (13.12 - 17.18) 1997 Modelled IHME
15 (13.12 - 17.19) 1996 Modelled IHME
15.03 (13.14 - 17.21) 1995 Modelled IHME
15.06 (13.18 - 17.28) 1994 Modelled IHME
15.1 (13.21 - 17.37) 1993 Modelled IHME
15.15 (13.25 - 17.45) 1992 Modelled IHME
15.2 (13.30 - 17.52) 1991 Modelled IHME
15.26 (13.33 - 17.65) 1990 Modelled IHME
5.47 (4.39 - 6.95) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
6.58 (5.38 - 7.98) 2019 Modelled IHME
6.93 (5.63 - 8.36) 2018 Modelled IHME
7.07 (5.74 - 8.52) 2017 Modelled IHME
7.01 (5.71 - 8.42) 2016 Modelled IHME
6.94 (5.69 - 8.34) 2015 Modelled IHME
6.94 (5.69 - 8.33) 2014 Modelled IHME
6.96 (5.69 - 8.37) 2013 Modelled IHME
6.98 (5.68 - 8.40) 2012 Modelled IHME
7.01 (5.70 - 8.45) 2011 Modelled IHME
7.04 (5.72 - 8.52) 2010 Modelled IHME
7.16 (5.82 - 8.66) 2009 Modelled IHME
7.41 (6.02 - 8.97) 2008 Modelled IHME
7.77 (6.32 - 9.39) 2007 Modelled IHME
8.18 (6.67 - 9.89) 2006 Modelled IHME
8.61 (7.02 - 10.42) 2005 Modelled IHME
9.25 (7.56 - 11.16) 2004 Modelled IHME
10.15 (8.29 - 12.23) 2003 Modelled IHME
11.08 (9.03 - 13.34) 2002 Modelled IHME
11.8 (9.61 - 14.23) 2001 Modelled IHME
12.1 (9.86 - 14.55) 2000 Modelled IHME
12.1 (9.89 - 14.58) 1999 Modelled IHME
12.09 (9.88 - 14.61) 1998 Modelled IHME
12.08 (9.87 - 14.58) 1997 Modelled IHME
12.07 (9.86 - 14.55) 1996 Modelled IHME
12.06 (9.85 - 14.56) 1995 Modelled IHME
12.03 (9.82 - 14.53) 1994 Modelled IHME
11.99 (9.75 - 14.50) 1993 Modelled IHME
11.94 (9.69 - 14.45) 1992 Modelled IHME
11.87 (9.63 - 14.40) 1991 Modelled IHME
11.8 (9.53 - 14.35) 1990 Modelled IHME
2.61 (1.96 - 3.47) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
39 (34 - 43) 2019 Modelled IHME
39 (34 - 43) 2018 Modelled IHME
39 (34 - 44) 2017 Modelled IHME
39 (34 - 44) 2016 Modelled IHME
39 (34 - 44) 2015 Modelled IHME
39 (35 - 44) 2014 Modelled IHME
39 (35 - 44) 2013 Modelled IHME
39 (35 - 44) 2012 Modelled IHME
40 (35 - 44) 2011 Modelled IHME
40 (35 - 45) 2010 Modelled IHME
40 (35 - 45) 2009 Modelled IHME
40 (36 - 45) 2008 Modelled IHME
40 (36 - 45) 2007 Modelled IHME
41 (36 - 45) 2006 Modelled IHME
41 (36 - 46) 2005 Modelled IHME
41 (36 - 46) 2004 Modelled IHME
41 (36 - 46) 2003 Modelled IHME
41 (36 - 45) 2002 Modelled IHME
41 (36 - 46) 2001 Modelled IHME
40 (36 - 46) 2000 Modelled IHME
40 (36 - 45) 1999 Modelled IHME
40 (35 - 45) 1998 Modelled IHME
40 (35 - 45) 1997 Modelled IHME
40 (35 - 45) 1996 Modelled IHME
39 (35 - 44) 1995 Modelled IHME
39 (35 - 44) 1994 Modelled IHME
39 (34 - 44) 1993 Modelled IHME
39 (34 - 44) 1992 Modelled IHME
39 (35 - 44) 1991 Modelled IHME
39 (35 - 44) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
57 2018 Survey/reported WHO/UNICEF
57 2017 Survey/reported WHO/UNICEF
57 2016 Survey/reported WHO/UNICEF
42 2015 Survey/reported WHO/UNICEF
43 2014 Survey/reported WHO/UNICEF
43 2013 Survey/reported WHO/UNICEF
42 2012 Survey/reported WHO/UNICEF
46 2011 Survey/reported WHO/UNICEF
49 2010 Survey/reported WHO/UNICEF
63 2009 Survey/reported WHO/UNICEF
41 2008 Survey/reported WHO/UNICEF
42 2007 Survey/reported WHO/UNICEF
27 2006 Survey/reported WHO/UNICEF
18 2005 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Eligible for HBV generic medicines
Year of birth dose introduction
2004
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.57 (2.05 - 3.23) 2019 Modelled IHME
2.57 (2.05 - 3.24) 2018 Modelled IHME
2.58 (2.05 - 3.25) 2017 Modelled IHME
2.59 (2.07 - 3.26) 2016 Modelled IHME
2.62 (2.10 - 3.28) 2015 Modelled IHME
2.67 (2.14 - 3.34) 2014 Modelled IHME
2.75 (2.20 - 3.44) 2013 Modelled IHME
2.84 (2.27 - 3.56) 2012 Modelled IHME
2.93 (2.34 - 3.69) 2011 Modelled IHME
3.02 (2.41 - 3.79) 2010 Modelled IHME
3.1 (2.47 - 3.90) 2009 Modelled IHME
3.18 (2.54 - 4) 2008 Modelled IHME
3.27 (2.60 - 4.09) 2007 Modelled IHME
3.35 (2.68 - 4.20) 2006 Modelled IHME
3.44 (2.75 - 4.31) 2005 Modelled IHME
3.55 (2.84 - 4.44) 2004 Modelled IHME
3.68 (2.95 - 4.61) 2003 Modelled IHME
3.81 (3.05 - 4.77) 2002 Modelled IHME
3.9 (3.13 - 4.88) 2001 Modelled IHME
3.94 (3.16 - 4.93) 2000 Modelled IHME
3.92 (3.15 - 4.91) 1999 Modelled IHME
3.87 (3.11 - 4.85) 1998 Modelled IHME
3.82 (3.06 - 4.78) 1997 Modelled IHME
3.77 (3.02 - 4.72) 1996 Modelled IHME
3.75 (3 - 4.70) 1995 Modelled IHME
3.76 (3 - 4.70) 1994 Modelled IHME
3.78 (3.02 - 4.73) 1993 Modelled IHME
3.81 (3.05 - 4.77) 1992 Modelled IHME
3.86 (3.08 - 4.84) 1991 Modelled IHME
3.92 (3.14 - 4.92) 1990 Modelled IHME
1 (1 - 1.40) 2015 Modelled Blach et al, 2017
6.9 (3.20 - 10.50) 2014 Modelled Gower et al, 2014
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
8.4 (3.90 - 12.80) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (18 - 25) 2019 Modelled IHME
21 (17 - 24) 2018 Modelled IHME
20 (17 - 24) 2017 Modelled IHME
20 (17 - 24) 2016 Modelled IHME
20 (17 - 24) 2015 Modelled IHME
20 (17 - 24) 2014 Modelled IHME
20 (17 - 24) 2013 Modelled IHME
20 (17 - 24) 2012 Modelled IHME
20 (17 - 24) 2011 Modelled IHME
20 (17 - 24) 2010 Modelled IHME
20 (17 - 24) 2009 Modelled IHME
20 (17 - 24) 2008 Modelled IHME
20 (17 - 24) 2007 Modelled IHME
20 (17 - 24) 2006 Modelled IHME
20 (17 - 24) 2005 Modelled IHME
20 (17 - 24) 2004 Modelled IHME
20 (17 - 24) 2003 Modelled IHME
20 (17 - 24) 2002 Modelled IHME
20 (17 - 24) 2001 Modelled IHME
20 (17 - 24) 2000 Modelled IHME
20 (17 - 24) 1999 Modelled IHME
20 (17 - 24) 1998 Modelled IHME
20 (17 - 24) 1997 Modelled IHME
20 (17 - 24) 1996 Modelled IHME
20 (17 - 24) 1995 Modelled IHME
20 (17 - 24) 1994 Modelled IHME
20 (17 - 24) 1993 Modelled IHME
20 (17 - 24) 1992 Modelled IHME
20 (17 - 24) 1991 Modelled IHME
20 (17 - 24) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Eligible for HBV generic medicines
Year of birth dose introduction
2004
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
9.9 (%)
2019
(8.61 - 11.33(%))
IHME
HCV (RNA/cAg+)
2.57 (%)
2019
(2.05 - 3.23(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
20,245
2019
(13,541 - 29,553)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,965
2019
(2,011 - 4,360)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
6.58 (%)
2019, latest modelled
(5.38 - 7.98(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines